The addition of monoclonal antibodies targeting human growth factor receptors, such as EGFR or HER2, to conventional chemotherapy has improved survival in patients with metastasized GC and CRC.12–14 However, the presence of activating mutations downstream of the targeted receptor or the lack of expression of the target renders this therapeutic approach inaccessible for most cancer patients. This evidence concerns the gene ERBB2 and gastric cancer.